Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $36.00

Posted by Brenda Bartman on Aug 13th, 2026

Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price objective hoisted by Royal Bank Of Canada from $33.00 to $36.00 in a research note released on Monday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

A number of other brokerages have also issued reports on NRIX. Robert W. Baird raised their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Oppenheimer assumed coverage on Nurix Therapeutics in a research note on Monday, June 29th. They issued an “outperform” rating and a $28.00 target price on the stock. Wells Fargo & Company downgraded Nurix Therapeutics from an “overweight” rating to a “hold” rating and reduced their price target for the stock from $28.00 to $25.00 in a research report on Monday, June 8th. Finally, HC Wainwright increased their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.21.

View Our Latest Stock Analysis on Nurix Therapeutics

Nurix Therapeutics Trading Up 2.6%

Shares of NASDAQ NRIX opened at $26.63 on Monday. Nurix Therapeutics has a 12-month low of $8.19 and a 12-month high of $26.82. The firm’s 50-day moving average price is $21.85 and its 200-day moving average price is $18.20. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of -7.72 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, equities analysts predict that Nurix Therapeutics will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $25.00, for a total value of $108,900.00. Following the sale, the insider owned 117,227 shares in the company, valued at $2,930,675. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 25,314 shares of company stock worth $589,361. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock worth $593,000 after purchasing an additional 5,286 shares in the last quarter. Millennium Management LLC raised its position in shares of Nurix Therapeutics by 106.2% during the 1st quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after buying an additional 450,262 shares during the period. Goldman Sachs Group Inc. raised its holdings in Nurix Therapeutics by 9.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after buying an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Nurix Therapeutics by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after acquiring an additional 12,817 shares during the period. Finally, Creative Planning purchased a new stake in Nurix Therapeutics in the second quarter valued at approximately $187,000.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.